Stratatech | Excellence in Regenerative Medicine Homepage

Press Releases

Stratatech
510 Charmany Drive
Suite 150
Madison, WI 53719

Phone (608) 441-2750
Fax (608) 441-2757

Press Releases

August 10, 2016
MALLINCKRODT TO ACQUIRE STRATATECH CORPORATION, A REGENERATIVE MEDICINE COMPANY FOCUSED ON PROPRIETARY THERAPEUTIC HUMAN SKIN SUBSTITUTE PRODUCTS

October 05, 2015
Stratatech Awarded BARDA Project BioShield Contract Valued up to $247 Million for StrataGraft® Skin Tissue for Thermal Burns

March 10, 2015
Stratatech Announces Positive Top-Line Results from Proof-of-Concept Study of StrataGraft® Skin Tissue in Patients with Severe Burns

July 31, 2013
Stratatech Awarded BARDA Contract Valued up to $47.2 Million for Advanced Development of StrataGraft® Skin Tissue for Thermal Burns

January 16, 2013
Stratatech Announces Impressive Clinical Results for StrataGraft ® Skin Tissue

June 13, 2012
Stratatech’s StrataGraft Skin Substitute® Granted FDA Orphan Drug Designation

April 27, 2012
Stratatech Reports Positive Interim Clinical Results for StrataGraft® Skin Substitute

October 31, 2011
Stratatech Awarded $4.6-Million Clinical Trial Grant for ExpressGraft™ Antimicrobial Skin Substitute

September 23, 2011
Stratatech initiates second clinical trial of StrataGraft® skin substitute

December 13, 2010
Stratatech makes strong addition to management team

November 16, 2010
Stratatech awarded $3.5 million to continue development of infection-fighting skin substitute

October 7, 2010
Defense Department funds next phase of Stratatech clinical trial

May 3, 2010
Stratatech Closes $3-Million Funding Round to Advance Clinical Trial

October 1, 2009
Stratatech Corp. receives $1.7 million grant for skin cancer treatment

© 2017 Stratatech a Mallinckrodt legal entity. All Rights Reserved. Internet Privacy Policy | Terms and Conditions | FCOI Policy
Site Design by Lakeshore Concepts